Vistagen Therapeutics Inc
(VTGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 12-2016 | 09-2016 | 06-2016 | 03-2016 | 12-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,372 | 6,257 | 8,500 | 429 | 1,158 |
| Receivables | 1,250 | N/A | N/A | N/A | N/A |
| TOTAL | $5,768 | $6,906 | $8,635 | $855 | $1,887 |
| Non-Current Assets | |||||
| PPE Net | 60 | 69 | 76 | 88 | 79 |
| Other Non-Current Assets | 48 | 48 | 47 | 47 | 47 |
| TOTAL | $108 | $117 | $123 | $135 | $126 |
| Total Assets | $5,876 | $7,023 | $8,758 | $990 | $2,012 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 874 | 930 | 930 | 936 | 1,098 |
| Accrued Expenses | 962 | 795 | 565 | 814 | 929 |
| TOTAL | $1,872 | $1,797 | $1,602 | $1,795 | $2,102 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | N/A | 27 | 29 |
| Other Non-Current Liabilities | 1,339 | 1,102 | 946 | 2,090 | 1,416 |
| TOTAL | $1,415 | $1,139 | $994 | $2,172 | $1,509 |
| Total Liabilities | $3,288 | $2,936 | $2,595 | $3,967 | $3,611 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 286 | 279 | 265 | 265 | 76 |
| Common Shares | 9 | 8 | 8 | 3 | 2 |
| Retained earnings | -139,450 | -136,811 | -133,710 | -131,743 | -123,242 |
| Other shareholders' equity | 32 | 32 | 32 | 32 | 32 |
| TOTAL | $2,589 | $4,087 | $6,163 | $-2,977 | $-1,598 |
| Total Liabilities And Equity | $5,876 | $7,023 | $8,758 | $990 | $2,012 |